Effect of <i>Bifidobacterium trisporus</i> on Intestinal Microbiota in the Mouse Model of Non-alcoholic Fatty Liver Disease

Chun LI; Qiong ZHOU; Cong MEI; Jie jie HUANG; Yi peng WANG; Song lan ZHOU; Qian ZHENG; Zhe TANG

doi:10.12259/j.issn.2095-610X.S20231022

Volume 44 Issue 10

Oct. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2023 > 44(10): 77-82

Chun LI, Qiong ZHOU, Cong MEI, Jie jie HUANG, Yi peng WANG, Song lan ZHOU, Qian ZHENG, Zhe TANG. Effect of Bifidobacterium trisporus on Intestinal Microbiota in the Mouse Model of Non-alcoholic Fatty Liver Disease[J]. Journal of Kunming Medical University, 2023, 44(10): 77-82. doi: 10.12259/j.issn.2095-610X.S20231022

Citation:

Chun LI, Qiong ZHOU, Cong MEI, Jie jie HUANG, Yi peng WANG, Song lan ZHOU, Qian ZHENG, Zhe TANG. Effect of Bifidobacterium trisporus on Intestinal Microbiota in the Mouse Model of Non-alcoholic Fatty Liver Disease[J]. Journal of Kunming Medical University, 2023, 44(10): 77-82. doi: 10.12259/j.issn.2095-610X.S20231022

Citation:

PDF( 2157 KB)

Effect of Bifidobacterium trisporus on Intestinal Microbiota in the Mouse Model of Non-alcoholic Fatty Liver Disease

doi: 10.12259/j.issn.2095-610X.S20231022

Dept. of Endocrinology，Kunming Yan'an Hospital ，Kunming Yunnan 650051，China

Received Date: 2023-05-29
Available Online: 2023-09-07
Publish Date: 2023-10-25

Abstract

Abstract

Objective To investigate the therapeutic effects of probiotics containing Bifidobacterium on a mouse model of non-alcoholic fatty liver disease （NAFLD） and its impact on the gut microbiota. Methods C57BL/6J mice were divided into three experimental groups. The control group （n = 10） of mice was fed a normal diet, the NAFLD model group （n = 10） was fed a high-fat diet, and the probiotics group （n = 10） was given Bifidobacteriumtrisporus treatment while using NAFLD model mice. HE staining was performed on paraffin sections of mouse liver from different groups at the end of the experiment to observe pathological changes. The 16S rRNA gene sequencing technique was used to detect the gut microbiota in each group of mice, followed by bioinformatics analysis. Results Compared with the control group, NAFLD mice showed increased accumulation of liver fat, increased number of lipid droplets, enlarged cells, and increased levels of serum alanine aminotransferase （ALT）（P < 0.0001）. After treatment with Bifidobacteriumtrisporus, the accumulation of liver fat in NAFLD mice decreased and serum ALT levels decreased （P < 0.0001）. Microbiota analysis of the intestinal tract identified 348 common species of microorganisms in the three groups. Functional analysis of the microbiota showed that the metabolic function of the intestinal microbiota in the Bifidobacterium group was intermediate between the control group and the NAFLD group; Bifidobacterium treatment was able to alter the abundance of specific intestinal microorganisms in the NAFLD model, and these intestinal microorganisms may be involved in the regulation of metabolic function pathways such as glutathione metabolism, purine metabolism, and sphingolipid metabolism in the body. Conclusion Bifidobacterium may improve NAFLD by regulating the function of the intestinal microbiota in a mouse model, and it has the potential to improve disordered lipid metabolism in the body.
- Non-alcoholic fatty liver disease （NAFLD）,
- Metagenomics,
- Living bifidobacteria,
- High-fat diet

FullText(HTML)

References(26)

References

[1]	Wagner R,Eckstein S S,Yamazaki H,et al. Metabolic implications of pancreatic fat accumulation[J]. Nat Rev Endocrinol,2022,18(1):43-54. doi: 10.1038/s41574-021-00573-3
[2]	Kwan S Y,Jiao J,Joon A,et al. Gut microbiome features associated with liver fibrosis in Hispanics,a population at high risk for fatty liver disease[J]. Hepatology,2022,5(4):955-967.
[3]	Kolodziejczyk A A,Zheng D,Shibolet O,et al. The role of the microbiome in NAFLD and NASH[J]. EMBO Mol Med,2019,11(2):e9302. doi: 10.15252/emmm.201809302
[4]	Safari Z,Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD)[J]. Cell Mol Life Sci,2019,76(8):1541-1558. doi: 10.1007/s00018-019-03011-w
[5]	Hu H,Lin A,Kong M,et al. Intestinal microbiome and NAFLD: Molecular insights and therapeutic perspectives[J]. J Gastroenterol,2020,55(2):142-158. doi: 10.1007/s00535-019-01649-8
[6]	Aron-Wisnewsky J,Vigliotti C,Witjes J,et al. Gut microbiota and human NAFLD: Disentangling microbial signatures from metabolic disorders[J]. Nat Rev Gastroenterol Hepatol,2020,17(5):279-297. doi: 10.1038/s41575-020-0269-9
[7]	Lau L H S,Wong S H. Microbiota,obesity and NAFLD[J]. Adv Exp Med Biol,2018,1061:111-125.
[8]	Canfora E E,Meex R C R,Venema K,et al. Gut microbial metabolites in obesity,NAFLD and T2DM[J]. Nat Rev Endocrinol,2019,15(5):261-273. doi: 10.1038/s41574-019-0156-z
[9]	Fan Y,Pedersen O. Gut microbiota in human metabolic health and disease[J]. Nat Rev Microbiol,2021,19(1):55-71. doi: 10.1038/s41579-020-0433-9
[10]	Bana B,Cabreiro F. The microbiome and aging[J]. Annu Rev Genet,2019,53:239-261. doi: 10.1146/annurev-genet-112618-043650
[11]	Suez J,Zmora N,Segal E,et al. The pros,cons,and many unknowns of probiotics[J]. Nat Med,2019,25(5):716-729. doi: 10.1038/s41591-019-0439-x
[12]	Qian X,Si Q,Lin G,et al. Bifidobacterium adolescentis is effective in relieving type 2 diabetes and may be related to its dominant core genome and gut microbiota modulation capacity[J]. Nutrients,2022,14(12):2479. doi: 10.3390/nu14122479
[13]	Fang Z,Pan T,Li L,et al. Bifidobacterium longum mediated tryptophan metabolism to improve atopic dermatitis via the gut-skin axis[J]. Gut Microbes,2022,14(1):2044723. doi: 10.1080/19490976.2022.2044723
[14]	Eng J M,Estall J L. Diet-induced models of non-alcoholic fatty liver disease: Food for thought on sugar,fat,and cholesterol[J]. Cells,2021,10(7):1805.P. doi: 10.3390/cells10071805
[15]	Zeng H,Larson K J,Cheng WH,et al. Advanced liver steatosis accompanies an increase in hepatic inflammation,colonic,secondary bile acids and Lactobacillaceae/Lachnospiraceae bacteria in C57BL/6 mice fed a high-fat diet[J]. J Nutr Biochem,2020,78:108336. doi: 10.1016/j.jnutbio.2019.108336
[16]	Yuan G,Tan M,Chen X. Punicic acid ameliorates obesity and liver steatosis by regulating gut microbiota composition in mice[J]. Food Funct,2021,12(17):7897-7908. doi: 10.1039/D1FO01152A
[17]	Wang H,Wang Q,Yang C,et al. Bacteroides acidifaciens in the gut plays a protective role against CD95-mediated liver injury[J]. Gut Microbes,2022,14(1):2027853. doi: 10.1080/19490976.2022.2027853
[18]	Nishimura N,Kaji K,Kitagawa K,et al. Intestinal permeability is a mechanical rheostat in the pathogenesis of liver cirrhosis[J]. Int J Mol Sci,2021,22(13):6921. doi: 10.3390/ijms22136921
[19]	Do M H,Oh M J,Lee H B,et al. Bifidobacterium animalis ssp. lactis MG741 reduces body weight and ameliorates nonalcoholic fatty liver disease via improving the gut permeability and amelioration of inflammatory cytokines[J]. Nutrients,2022,14(9):1965. doi: 10.3390/nu14091965
[20]	Wang W,Xu A L,Li Z C,et al. Combination of probiotics and salvia miltiorrhiza polysaccharide alleviates hepatic steatosis via gut microbiota modulation and insulin resistance improvement in high fat-induced NAFLD mice[J]. Diabetes Metab J,2020,44(2):336-348. doi: 10.4093/dmj.2019.0042
[21]	Yang X,Mo W,Zheng C,et al. Alleviating effects of noni fruit polysaccharide on hepatic oxidative stress and inflammation in rats under a high-fat diet and its possible mechanisms[J]. Food Funct,2020,11(4):2953-2968. doi: 10.1039/D0FO00178C
[22]	Wang X,Shi L,Wang X,et al. MDG-1,an Ophiopogon polysaccharide,restrains process of non-alcoholic fatty liver disease via modulating the gut-liver axis[J]. Int J Biol Macromol,2019,141(3):1013-1021.
[23]	Tong A J,Hu R K,Wu L X,et al. Ganoderma polysaccharide and chitosan synergistically ameliorate lipid metabolic disorders and modulate gut microbiota composition in high fat diet-fed golden hamsters[J]. J Food Biochem,2020,44(1):e13109.
[24]	Dehhaghi M, Kazemi Shariat Panahi H, Guillemin GJ. Microorganisms, tryptophan metabolism, and kynurenine pathway: A complex interconnected loop influencing human health status [J]. Int J Tryptophan Res, 2019, 12（2）: 1178646919852996.
[25]	Arnoriaga-Rodríguez M,Mayneris-Perxachs J,Burokas A,et al. Obesity impairs short-term and working memory through gut microbial metabolism of aromatic amino acids[J]. Cell Metab,2020,32(4):548-560,e7. doi: 10.1016/j.cmet.2020.09.002
[26]	Zhao Z H,Xin F Z,Xue Y,et al. Indole-3-propionic acid inhibits gut dysbiosis and endotoxin leakage to attenuate steatohepatitis in rats[J]. Exp Mol Med,2019,51(9):1-14.

Relative Articles(20)

Relative Articles

[1]	Hang CHEN, Qi CUI, Minshan HUANG, Jianjun LIU, Lanqing MA. Research Progress of miRNA in Non-alcoholic Fatty Liver Disease. Journal of Kunming Medical University, 2024, 45(1): 1-7. doi: 10.12259/j.issn.2095-610X.S20240101
[2]	Yuanyuan LI, Yaxian SONG, Yushan XU, Xiaofu ZENG, Hui YUAN, Zhao XU, Yan JIANG. The Association of Intestinal Flora Metabolite TMAO with Non-alcoholic Fatty Liver Disease. Journal of Kunming Medical University, 2024, 45(2): 77-84. doi: 10.12259/j.issn.2095-610X.S20240210
[3]	Xuemin ZHANG, Yunfen TIAN. Role of Abnormal Bile Acid Metabolism in the Development of Non-alcoholic Fatty Liver Disease. Journal of Kunming Medical University, 2023, 44(11): 164-169. doi: 10.12259/j.issn.2095-610X.S20231125
[4]	Liyuan WANG, Zhenting YANG, Qingling LI, Haiwen LI, Zhirong ZHAO, Yongrui YANG, Shude LI. Effects of Scutellarin on MMP2，MMP9 and TIMP-1 Protein in Liver of Obese Rats with Chronic Liver Injury by High Glucose and Fat Diet. Journal of Kunming Medical University, 2023, 44(4): 9-15. doi: 10.12259/j.issn.2095-610X.S20230408
[5]	Lu LI, Yunfen TIAN. Research Progress on Intestinal Microflora and Non-alcoholic Fatty Liver Disease in Children. Journal of Kunming Medical University, 2023, 44(7): 148-155. doi: 10.12259/j.issn.2095-610X.S20230708
[6]	Yongrui YANG, Liyuan WANG, Haiwen LI, Zhirong ZHAO, Rui PU, Guishuai WU, Shude LI. Scutellarin Ameliorates Liver Fibrosis in Nonalcoholic Fatty Liver Disease by Inhibiting NOX Expression. Journal of Kunming Medical University, 2022, 43(7): 38-45. doi: 10.12259/j.issn.2095-610X.S20220721
[7]	Yong-fang XU, Na WU, Yue-xin HU, Yong-mei ZHAO, Shao-ding ZHENG, Ling WEI, Si-jia ZHENG, Jian-jun LIU. Therapeutic Effect of GW7647 on Non-alcoholic Fatty Liver Disease in Rats. Journal of Kunming Medical University, 2021, 42(8): 17-22. doi: 10.12259/j.issn.2095-610X.S20210804
[8]	Dai Run , Zhang Chan , Cheng Yu Jing , Chen Wan Lu , Li Qi , Wang Yu Ming . . Journal of Kunming Medical University, 2020, 41(05): 33-40.
[9]	Yang Huai Yong , Li Lin Da . . Journal of Kunming Medical University, 2020, 41(04): 111-116.
[10]	Ping-yan XUE, Yan JIANG, Yu-shan XU, Hui YUAN, Xuan LI, Ya-xian SONG, Hua LIU. Changes of Intestinal Flora in Non-alcoholic Fatty Liver Disease. Journal of Kunming Medical University, 2020, 41(11): 62-67. doi: 10.12259/j.issn.2095-610X.S20201120
[11]	Zhang Dan , Lv Jun Yan , Deng Yi , Zhou Bo , Luo Su Feng , Wang Jin Xiang , Wen Yu , Ying Yun Yan , Wen Dai Yan , Ma Lan Qing . . Journal of Kunming Medical University, 2020, 41(01): 11-17.
[12]	Zhu Wei Mei , Hua Peng , Luo Yu Chao , Yang Hong Ling , Li Ya Shan , Zhao Hong Yu . . Journal of Kunming Medical University, 2019, 40(02): 23-29.
[13]	Yang Jin Rong , Ruan Jing Yan , Zeng Yun , Wu Kun , Nie Bo , Wang Xue Jiao . . Journal of Kunming Medical University, 2019, 40(09): 12-17.
[14]	Tian Wei . Liraglutide Improves The Symptoms of Non-alcoholic Fatty Liver Disease by Regulating Fatty Acid β-oxidation. Journal of Kunming Medical University,
[15]	Zhang Xin Wen , Zhang Yan , Hu Yan Xin , Pan Bao Long , Wang Ming Fang , Ma Run Mei . Establishment of Gestational Diabetes Rat Model Induced by High-fat Diet. Journal of Kunming Medical University, 2016, 37(11): 8-13.
[16]	Wang Li Kun . . Journal of Kunming Medical University,
[17]	Jiang Yan . . Journal of Kunming Medical University,
[18]	Liu Rong . . Journal of Kunming Medical University,
[19]	Li Ying Fu . . Journal of Kunming Medical University,
[20]	He Hai Yu . . Journal of Kunming Medical University,